Metabolomics reveal 1-palmitoyl lysophosphatidylcholine production by peroxisome proliferator-activated receptor α

Journal of Lipid Research

Volumn 56, Issue 2, 2015, Pages 254-265

  Takahashi, Haruya ^a   Goto, Tsuyoshi ^a   Yamazaki, Yota ^a   Kamakari, Kosuke ^a   Hirata, Mariko ^a   Suzuki, Hideyuki ^b   Shibata, Daisuke ^b   Nakata, Rieko ^c   Inoue, Hiroyasu ^c   Takahashi, Nobuyuki ^a   Kawada, Teruo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KAZUSA DNA RESEARCH INSTITUTE   (Japan)

^c NARA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Liver; Lysoglycerophospholipid; Mass spectrometry; Omics; Phospholipases A2

Indexed keywords

BEZAFIBRATE; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLCHOLINE; PROTEIN LPC; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; LYSOPHOSPHATIDYLCHOLINE; WE 201;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE; GENE EXPRESSION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; LIVER CELL; MALE; METABOLOME; METABOLOMICS; MOUSE; NONHUMAN; PHOSPHOLIPID METABOLISM; PHOSPHOLIPID SYNTHESIS; PLA2G7 GENE; PROTEIN SECRETION; UPREGULATION; 3T3 CELL LINE; ANIMAL; BLOOD; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID METABOLISM; METABOLISM;

3T3-L1 CELLS; ANIMALS; BEZAFIBRATE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEPATOCYTES; INSULIN RESISTANCE; LIPID METABOLISM; LYSOPHOSPHATIDYLCHOLINES; MALE; METABOLOMICS; MICE; PPAR ALPHA; RNA, SMALL INTERFERING;

EID: 84921929417     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M052464     Document Type: Article

References (56)

1. Reilly, M. P., and D. J. Rader. 2003. The metabolic syndrome: more than the sum of its parts? Circulation. 108: 1546-1551.
2. Miranda, P. J., R. A. DeFronzo, R. M. Califf, and J. R. Guyton. 2005. Metabolic syndrome: definition, pathophysiology, and mechanism. Am. Heart J. 149: 33-45.
3. Kahn, B. B., and J. S. Flier. 2000. Obesity and insulin resistance. J. Clin. Invest. 106: 473-481.
4. Ginsberg, H. N. 2000. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106: 453-458.
5. Escher, P., and W. Wahli. 2000. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res. 448: 121-138.
6. Desvergne, B., and W. Wahli. 1999. Peroxisome proliferatoractivated receptors: nuclear control of metabolism. Endocr. Rev. 20: 649-688.
7. Chinetti, G., J. C. Fruchart, and B. Staeles. 2000. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49: 497-505.
8. Duval, C., G. Chinetti, F. Trottein, J. C. Fruchart, and B. Staeles. 2002. The role of PPARs in atherosclerosis. Trends Mol. Med. 8: 422-430.
9. Goldenberg, I., M. Benderly, and U. Goldbourt. 2008. Update on the use of fibrates: focus on bezafibrate. Vasc. Health Risk Manag. 4: 131-141.
10. Bernal-Mizrachi, C., S. Weng, C. Feng, B. N. Finck, R. H. Knutsen, T. C. Leone, T. Coleman, R. P. Mecham, D. P. Kelly, and C. F. Semenkovich. 2003. Dexamethasone induction of hypertension and diabetes is PPARα dependent in LDL receptor-null mice. Nat. Med. 9: 1069-1075.
11. Reddy, J. K., and T. Hashimoto. 2001. Peroxisomal β -oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21: 193-230.
12. Tugwood, J. D., I. Issemann, R. G. Anderson, K. R. Bundell, W. L. McPheat, and S. Green. 1992. The mouse peroxisome proliferators activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11: 433-439.
13. Roepstorff, C., N. Halberg, T. Hillig, A. K. Saha, N. B. Ruderman, J. F. Wojtaszewski, E. A. Richter, and B. Kiens. 2005. Malonyl-CoA and carnitine in regulation of fat oxidation in human skeletal muscle during exercise. Am. J. Physiol. Endocrinol. Metab. 288: E133-E142.
14. Miller, C. W., and J. M. Ntambi. 1996. Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proc. Natl. Acad. Sci. USA. 93: 9443-9448.
15. Grygiel-Górniak, B. 2014. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutr. J. 13: 17.
16. Kim, S., H. J. Shin, S. Y. Kim, J. H. Kim, Y. S. Lee, D. H. Kim, and M. O. Lee. 2004. Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha. Mol. Cell. Endocrinol. 220: 51-58.
17. Ericsson, C. G., A. Hamsten, J. Nilsson, L. Grip, B. Svane, and U. de Faire. 1996. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347: 849-853.
18. Tenenbaum, A., E. Z. Fisman, V. Boyko, M. Benderly, D. Tanne, M. Haim, Z. Matas, M. Motro, and S. Behar. 2006. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch. Intern. Med. 166: 737-741.
19. Tenenbaum, A., M. Motro, E. Z. Fisman, E. Schwammenthal, Y. Adler, I. Goldenberg, J. Leor, V. Boyko, L. Mandelzweig, and S. Behar. 2004. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 109: 2197-2202.
20. Tenenbaum, A., M. Motro, E. Z. Fisman, D. Tanne, V. Boyko, and S. Behar. 2005. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 165: 1154-1160.
21. Hu, C., M. Hoene, X. Zhao, H. U. Häring, E. Schleicher, R. Lehmann, X. Han, G. Xu, and C. Weigert. 2010. Lipidomics analysis reveals efficient storage of hepatic triacylglycerides enriched in unsaturated fatty acids after one bout of exercise in mice. PLoS ONE. 5: e13318.
22. Iijima, Y., Y. Nakamura, Y. Ogata, K. Tanaka, N. Sakurai, K. Suda, T. Suzuki, H. Suzuki, K. Okazaki, M. Kitayama, et al. 2008. Metabolite annotations based on the integration of mass spectral information. Plant J. 54: 949-962.
23. Kim, Y. I., S. Hirai, H. Takahashi, T. Goto, C. Ohyane, T. Tsugane, C. Konishi, T. Fujii, S. Inai, Y. Iijima, et al. 2011. 9-oxo-10(E),12(E)- octadecadienoic acid derived from tomato is a potent PPARα agonist to decrease triglyceride accumulation in mouse primary hepatocytes. Mol. Nutr. Food Res. 55: 585-593.
24. Goto, T., H. Nagai, K. Egawa, Y-I. Kim, S. Kato, A. Taimatsu, T. Sakamoto, S. Ebisu, T. Hohsaka, H. Miyagawa, et al. 2011. Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARα agonist. Biochem. J. 438: 111-119.
25. Takahashi, N., T. Kawada, T. Goto, T. Yamamoto, A. Taimatsu, N. Matsui, K. Kimura, M. Saito, M. Hosokawa, K. Miyashita, et al. 2002. Dual action of isoprenols from herbal medicines on both PPARγ and PPARα in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett. 514: 315-322.
26. Goto, T., N. Takahashi, S. Kato, K. Egawa, S. Ebisu, T. Moriyama, T. Fushiki, and T. Kawada. 2005. Phytol directly activates peroxisome proliferator-activated receptorα (PPARα ) and regulates gene expression involved in lipid metabolism in PPARα -expressing HepG2 hepatocytes. Biochem. Biophys. Res. Commun. 337: 440-445.
27. Chen, X. H., Y. P. Zhao, M. Xue, C. B. Ji, C. L. Gao, J. G. Zhu, D. N. Qin, C. Z. Kou, X. H. Qin, M. L. Tong, et al. 2010. TNF-alpha induces mitochondrial dysfunction in 3T3-L1 adipocytes. Mol. Cell. Endocrinol. 328: 63-69.
28. Permana, P. A., C. Menge, and P. D. Reaven. 2006. Macrophagesecreted factors induce adipocyte inflammation and insulin resistance. Biochem. Biophys. Res. Commun. 341: 507-514.
29. Goto, T., J. Y. Lee, A. Teraminami, Y-I. Kim, S. Hirai, T. Uemura, H. Inoue, N. Takahashi, and T. Kawada. 2011. Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes. J. Lipid Res. 52: 873-884.
30. Takahashi, N., T. Kawada, T. Goto, C. S. Kim, A. Taimatsu, K. Egawa, T. Yamamoto, M. Jisaka, K. Nishimura, K. Yokota, et al. 2003. Abietic acid activates peroxisome proliferator-activated receptor-(PPAR) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism. FEBS Lett. 550: 190-194.
31. Yea, K., J. Kim, J. H. Yoon, T. Kwon, J. H. Kim, B. D. Lee, H. Lee, S. J. Lee, J. Kim, T. G. Lee, et al. 2009. Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J. Biol. Chem. 284: 33833-33840.
32. Zhao, X., A. Peter, J. Fritsche, M. Elcnerova, A. Fritsche, H. U. Häring, E. D. Schleicher, G. Xu, and R. Lehmann. 2009. Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am. J. Physiol. Endocrinol. Metab. 296: E384-E393.
33. Birgbauer, E., and J. Chun. 2006. New developments in the biological functions of lysophospholipids. Cell. Mol. Life Sci. 63: 2695-2701.
34. Xu, Y., X. J. Fang, G. Casey, and G. B. Mills. 1995. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309: 933-940.
35. Rosenblat, M., R. Oren, and M. Aviram. 2006. Lysophosphatidylcholine (LPC) attenuates macrophage-mediated oxidation of LDL. Biochem. Biophys. Res. Commun. 344: 1271-1277.
36. Murugesan, G., M. R. Sandhya Rani, C. E. Gerber, C. Mukhopadhyay, R. M. Ransohoff, G. M. Chisolm, and K. Kottke-Marchant. 2003. Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. J. Mol. Cell. Cardiol. 35: 1375-1384.
37. Schmitz, G., and K. Ruebsaamen. 2010. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis. 208: 10-18.
38. Balogun, K. A., C. J. Albert, D. A. Ford, R. J. Brown, and S. K. Cheema. 2013. Dietary omega-3 polyunsaturated fatty acids after the fatty acid composition of hepatic and plasma bioactive lipids in C57BL/6 mice: a lipidomic approach. PLoS ONE. 8: e82399.
39. 2γ. J. Biol. Chem. 280: 26669-26679.
40. Hespel, P., L. Vergauwen, K. Vandenberghe, and E. A. Richter. 1996. Significance of insulin for glucose metabolism in skeletal muscle during contractions. Diabetes. 45: S99-S104.
41. Fernández-Real, J. M., and W. Ricart. 2003. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr. Rev. 24: 278-301.
42. Dandona, P., A. Aljada, and A. Bandyopadhyay. 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25: 4-7.
43. Wellen, K. E., and G. S. Hotamisligil. 2003. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112: 1785-1788.
44. Hotamisligil, G. S., N. S. Shargill, and B. M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259: 87-91.
45. Hotamisligil, G. S., D. L. Murray, L. N. Choy, and B. M. Spiegelman. 1994. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA. 91: 4854-4858.
46. Hotamisligil, G. S., P. Arner, J. F. Caro, R. L. Atkinson, and B. M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
47. Saghizadeh, M., J. M. Ong, W. T. Garvey, R. R. Henry, and P. A. Kern. 1996. The expression of TNF α by human muscle. Relationship to insulin resistance. J. Clin. Invest. 97: 1111-1116.
48. Parks, B. W., G. P. Gambill, A. J. Lusis, and J. H. Kabarowski. 2005. Loss of G2A promotes macrophage accumulation in atherosclerotic lesions of low density lipoprotein receptor-deficient mice. J. Lipid Res. 46: 1405-1415.
49. Huang, F., P. V. Subbaiah, O. Holian, J. Zhang, A. Johnson, N. Gertzberg, and H. Lum. 2005. Lysophosphatidylcholine increases endothelial permeability: role of PKCα and RhoA cross talk. Am. J. Physiol. Lung Cell. Mol. Physiol. 289: L176-L185.
50. Yamamoto, M., H. Hara, and T. Adachi. 2002. The expression of extracellular-superoxide dismutase is increased by lysophosphatidylcholine in human monocytic U937 cells. Atherosclerosis. 163: 223-228.
51. Suganami, T., K. Tanimoto-Koyama, J. Nishida, M. Itoh, X. Yuan, S. Mizuarai, H. Kotani, S. Yamaoka, K. Miyake, S. Aoe, et al. 2007. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 27: 84-91.
52. Ohto, U., K. Fukase, K. Miyake, and Y. Satow. 2007. Crystal structures of human MD-2 and its complex with antiendotoxic lipid Iva. Science. 316: 1632-1634.
53. Takahashi, H., H. Suzuki, K. Suda, Y. Yamazaki, A. Takino, Y-I. Kim, T. Goto, Y. Iijima, K. Aoki, D. Shibata, et al. 2013. Long-chain free fatty acid profiling analysis by liquid chromatography-mass spectrometry in mouse treated with peroxisome proliferator-activated receptor α agonist. Biosci. Biotechnol. Biochem. 77: 2288-2293.
54. Barber, M. N., S. Risis, C. Yang, P. J. Meikle, M. Staples, M. A. Febbraio, and C. R. Bruce. 2012. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS ONE. 7: e41456.
55. Srivastava, R. A. 2009. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists. Eur. J. Pharmacol. 607: 258-263.
56. Tsuchida, A., T. Yamauchi, S. Takekawa, Y. Hada, Y. Ito, T. Maki, and T. Kadowaki. 2005. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 54: 3358-3370.